PPA
LGND icon

Parametric Portfolio Associates’s Ligand Pharmaceuticals LGND Stock Holding History

Parametric Portfolio Associates’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$7.51M Sell
106,973
-4,161
-4% -$302K ﹤0.01% 1565
2021
Q4 		$10.7M Sell
111,134
-4,441
-4% -$410K 0.01% 1325
2021
Q3 		$10M Buy
115,575
+29,839
+35% +$2.31M 0.01% 1353
2021
Q2 		$7.02M Sell
85,736
-5,669
-6% -$472K ﹤0.01% 1624
2021
Q1 		$8.69M Sell
91,405
-148,061
-62% -$14M 0.01% 1782
2020
Q4 		$14.9M Sell
239,466
-25,343
-10% -$1.44M 0.01% 1272
2020
Q3 		$15.7M Sell
264,809
-9,889
-4% -$675K 0.01% 1057
2020
Q2 		$19.2M Sell
274,698
-27,206
-9% -$1.72M 0.01% 903
2020
Q1 		$13.7M Sell
301,904
-3,153
-1% -$179K 0.01% 1019
2019
Q4 		$19.8M Buy
305,057
+59,187
+24% +$3.96M 0.01% 988
2019
Q3 		$15.3M Sell
245,870
-53,402
-18% -$3.35M 0.01% 1113
2019
Q2 		$21.3M Sell
299,272
-895
-0.3% -$65.9K 0.02% 889
2019
Q1 		$23.5M Buy
300,167
+75,420
+34% +$5.71M 0.02% 793
2018
Q4 		$19M Sell
224,747
-56,974
-20% -$6.07M 0.02% 834
2018
Q3 		$48.2M Sell
281,721
-36,450
-11% -$5.5M 0.04% 398
2018
Q2 		$41.1M Sell
318,171
-20,445
-6% -$2.28M 0.04% 438
2018
Q1 		$34.9M Buy
338,616
+40,577
+14% +$4.01M 0.03% 514
2017
Q4 		$25.5M Sell
298,039
-25,813
-8% -$2.24M 0.03% 654
2017
Q3 		$27.5M Buy
323,852
+23,139
+8% +$1.83M 0.03% 582
2017
Q2 		$22.8M Buy
300,713
+37,500
+14% +$2.62M 0.03% 612
2017
Q1 		$17.4M Sell
263,213
-41,596
-14% -$2.74M 0.03% 713
2016
Q4 		$19.3M Buy
304,809
+19,395
+7% +$1.22M 0.03% 621
2016
Q3 		$18.2M Buy
285,414
+28,665
+11% +$2.1M 0.03% 599
2016
Q2 		$19.1M Sell
256,749
-54,526
-18% -$4.05M 0.03% 561
2016
Q1 		$20.8M Buy
311,275
+260,051
+508% +$15.8M 0.03% 511
2015
Q4 		$3.46M Buy
51,224
+18,667
+57% +$1.15M 0.01% 1723
2015
Q3 		$1.74M Buy
32,557
+330
+1% +$20K ﹤0.01% 1949
2015
Q2 		$2.03M Buy
32,227
+4,963
+18% +$271K ﹤0.01% 2234
2015
Q1 		$1.31M Buy
27,264
+12,306
+82% +$471K ﹤0.01% 2578
2014
Q4 		$497K Buy
+14,958
New +$487K ﹤0.01% 3273
2014
Q3 		– Sell
-9,039
Closed -$351K – 3845
2014
Q2 		$351K Sell
9,039
-1,762
-16% -$71.5K ﹤0.01% 3428
2014
Q1 		$453K Buy
10,801
+3,374
+45% +$141K ﹤0.01% 3228
2013
Q4 		$244K Sell
7,427
-4,895
-40% -$159K ﹤0.01% 3524
2013
Q3 		$333K Sell
12,322
-17,758
-59% -$500K ﹤0.01% 3337
2013
Q2 		$702K Buy
+30,080
New +$541K ﹤0.01% 2711

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Parametric Portfolio Associates's LGND Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Ligand Pharmaceuticals (LGND) stake by 3.7% in Q1 2022, selling an estimated $302K and leaving 106,973 shares worth $7.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1565.

Parametric Portfolio Associates first reported a position in LGND in Q2 2013 and has held it in 35 quarters since. The position peaked at $48.2M in Q3 2018. 208 funds tracked by Wall St. Rank hold LGND as of Q1 2022.

  • Parametric Portfolio Associates held 106,973 shares of Ligand Pharmaceuticals worth $7.51M as of Q1 2022.
  • Parametric Portfolio Associates sold 4,161 Ligand Pharmaceuticals shares in Q1 2022, an estimated $302K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1565 holding.
  • Parametric Portfolio Associates first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
  • Parametric Portfolio Associates's Ligand Pharmaceuticals position peaked at $48.2M in Q3 2018.
  • 208 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.